Do analysts rate NOG or VAL?

Nostrum Oil & Gas presently has a consensus target price of GBX 4, suggesting a potential upside of 24.96%. Given Nostrum Oil & Gas' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nostrum Oil & Gas is more favorable than ValiRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nostrum Oil & Gas 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ValiRx 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NOG or VAL more profitable?

Nostrum Oil & Gas has a net margin of -184.95% compared to ValiRx's net margin of -3,582.56%. Nostrum Oil & Gas' return on equity of 88.74% beat ValiRx's return on equity. Company Net Margins Return on Equity Return on Assets Nostrum Oil & Gas -184.95% 88.74% 1.53% ValiRx -3,582.56% -45.91% -35.98%

Is VAL or WRES more profitable?

W Resources has a net margin of -174.96% compared to ValiRx's net margin of -3,582.56%. W Resources' return on equity of -33.02% beat ValiRx's return on equity. Company Net Margins Return on Equity Return on Assets ValiRx -3,582.56% -45.91% -35.98% W Resources -174.96% -33.02% -2.04%

Is VAL or CRC more profitable?

Circle Property has a net margin of 32.17% compared to ValiRx's net margin of -3,582.56%. Circle Property's return on equity of 3.15% beat ValiRx's return on equity. Company Net Margins Return on Equity Return on Assets ValiRx -3,582.56% -45.91% -35.98% Circle Property 32.17% 3.15% 1.48%

Which has higher valuation and earnings, WEB or VAL?

Webis has higher revenue and earnings than ValiRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Webis £49.70M 0.00 N/A N/A N/A ValiRx £49.78K 29.85 -£5.71M -£0.93 N/A

Is WEB or VAL more profitable?

Webis has a net margin of -1.93% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat Webis' return on equity. Company Net Margins Return on Equity Return on Assets Webis -1.93% -187.51% -8.29% ValiRx -3,582.56% -45.91% -35.98%

ValiRx (VAL) Competitors

GBX 0.20 +0.01 (+5.26%)

As of 06:14 AM Eastern

Compare

VAL vs. NOG, SUN, WRES, CRC, and WEB

Should you buy ValiRx stock or one of its competitors? MarketBeat compares ValiRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ValiRx include Nostrum Oil & Gas (NOG), Surgical Innovations Group (SUN), W Resources (WRES), Circle Property (CRC), and Webis (WEB). These companies are all part of the "petroleum and natural gas" industry.

How does ValiRx compare to Nostrum Oil & Gas?

Nostrum Oil & Gas (LON:NOG) and ValiRx (LON:VAL) are both small-cap petroleum and natural gas companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

ValiRx has lower revenue, but higher earnings than Nostrum Oil & Gas. ValiRx is trading at a lower price-to-earnings ratio than Nostrum Oil & Gas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nostrum Oil & Gas	£121.19M	0.04	-£121.71M	-£235.00	N/A
ValiRx	£49.78K	29.85	-£5.71M	-£0.93	N/A

Nostrum Oil & Gas presently has a consensus target price of GBX 4, suggesting a potential upside of 24.96%. Given Nostrum Oil & Gas' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nostrum Oil & Gas is more favorable than ValiRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nostrum Oil & Gas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ValiRx	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nostrum Oil & Gas has a net margin of -184.95% compared to ValiRx's net margin of -3,582.56%. Nostrum Oil & Gas' return on equity of 88.74% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nostrum Oil & Gas	-184.95%	88.74%	1.53%
ValiRx	-3,582.56%	-45.91%	-35.98%

9.7% of Nostrum Oil & Gas shares are owned by institutional investors. Comparatively, 35.4% of ValiRx shares are owned by institutional investors. 34.5% of Nostrum Oil & Gas shares are owned by insiders. Comparatively, 7.9% of ValiRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nostrum Oil & Gas has a beta of 0.718, indicating that its share price is 28% less volatile than the broader market. Comparatively, ValiRx has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, Nostrum Oil & Gas had 1 more articles in the media than ValiRx. MarketBeat recorded 1 mentions for Nostrum Oil & Gas and 0 mentions for ValiRx. ValiRx's average media sentiment score of 1.05 beat Nostrum Oil & Gas' score of 0.00 indicating that ValiRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Nostrum Oil & Gas	Neutral
ValiRx	Positive

Summary

Nostrum Oil & Gas beats ValiRx on 10 of the 15 factors compared between the two stocks.

How does ValiRx compare to Surgical Innovations Group?

Surgical Innovations Group (LON:SUN) and ValiRx (LON:VAL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Surgical Innovations Group has a net margin of -4.96% compared to ValiRx's net margin of -3,582.56%. Surgical Innovations Group's return on equity of -6.04% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgical Innovations Group	-4.96%	-6.04%	-3.03%
ValiRx	-3,582.56%	-45.91%	-35.98%

Surgical Innovations Group has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, ValiRx has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

2.8% of Surgical Innovations Group shares are held by institutional investors. Comparatively, 35.4% of ValiRx shares are held by institutional investors. 21.5% of Surgical Innovations Group shares are held by insiders. Comparatively, 7.9% of ValiRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Surgical Innovations Group has higher revenue and earnings than ValiRx. Surgical Innovations Group is trading at a lower price-to-earnings ratio than ValiRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgical Innovations Group	£11.60M	0.37	N/A	-£0.10	N/A
ValiRx	£49.78K	29.85	-£5.71M	-£0.93	N/A

In the previous week, ValiRx's average media sentiment score of 1.05 beat Surgical Innovations Group's score of 0.75 indicating that ValiRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Surgical Innovations Group	Positive
ValiRx	Positive

Summary

Surgical Innovations Group beats ValiRx on 7 of the 11 factors compared between the two stocks.

How does ValiRx compare to W Resources?

ValiRx (LON:VAL) and W Resources (LON:WRES) are both small-cap petroleum and natural gas companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

ValiRx has higher earnings, but lower revenue than W Resources. ValiRx is trading at a lower price-to-earnings ratio than W Resources, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ValiRx	£49.78K	29.85	-£5.71M	-£0.93	N/A
W Resources	£3.47M	0.00	-£6.06M	-£6.10	N/A

W Resources has a net margin of -174.96% compared to ValiRx's net margin of -3,582.56%. W Resources' return on equity of -33.02% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ValiRx	-3,582.56%	-45.91%	-35.98%
W Resources	-174.96%	-33.02%	-2.04%

35.4% of ValiRx shares are owned by institutional investors. Comparatively, 4.6% of W Resources shares are owned by institutional investors. 7.9% of ValiRx shares are owned by company insiders. Comparatively, 28.0% of W Resources shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ValiRx's average media sentiment score of 1.05 beat W Resources' score of 0.00 indicating that ValiRx is being referred to more favorably in the media.

Company	Overall Sentiment
ValiRx	Positive
W Resources	Neutral

ValiRx has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, W Resources has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

W Resources beats ValiRx on 6 of the 11 factors compared between the two stocks.

How does ValiRx compare to Circle Property?

ValiRx (LON:VAL) and Circle Property (LON:CRC) are both small-cap petroleum and natural gas companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Circle Property has higher revenue and earnings than ValiRx. ValiRx is trading at a lower price-to-earnings ratio than Circle Property, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ValiRx	£49.78K	29.85	-£5.71M	-£0.93	N/A
Circle Property	£7.57M	0.00	£2.43M	£0.07	N/A

Circle Property has a net margin of 32.17% compared to ValiRx's net margin of -3,582.56%. Circle Property's return on equity of 3.15% beat ValiRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ValiRx	-3,582.56%	-45.91%	-35.98%
Circle Property	32.17%	3.15%	1.48%

35.4% of ValiRx shares are owned by institutional investors. Comparatively, 11.4% of Circle Property shares are owned by institutional investors. 7.9% of ValiRx shares are owned by insiders. Comparatively, 63.7% of Circle Property shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ValiRx's average media sentiment score of 1.05 beat Circle Property's score of 0.00 indicating that ValiRx is being referred to more favorably in the media.

Company	Overall Sentiment
ValiRx	Positive
Circle Property	Neutral

ValiRx has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Circle Property has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

Circle Property beats ValiRx on 8 of the 11 factors compared between the two stocks.

How does ValiRx compare to Webis?

Webis (LON:WEB) and ValiRx (LON:VAL) are both small-cap petroleum and natural gas companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Webis has a net margin of -1.93% compared to ValiRx's net margin of -3,582.56%. ValiRx's return on equity of -45.91% beat Webis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Webis	-1.93%	-187.51%	-8.29%
ValiRx	-3,582.56%	-45.91%	-35.98%

Webis has higher revenue and earnings than ValiRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Webis	£49.70M	0.00	N/A	N/A	N/A
ValiRx	£49.78K	29.85	-£5.71M	-£0.93	N/A

35.4% of ValiRx shares are owned by institutional investors. 63.1% of Webis shares are owned by insiders. Comparatively, 7.9% of ValiRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ValiRx's average media sentiment score of 1.05 beat Webis' score of 0.00 indicating that ValiRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Webis	Neutral
ValiRx	Positive

Webis has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, ValiRx has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Summary

Webis beats ValiRx on 6 of the 9 factors compared between the two stocks.

Get ValiRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAL vs. The Competition

Export

Metric	ValiRx	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.49M	£456.46M	£6.47B	£2.77B
Dividend Yield	0.63%	3.87%	2.69%	6.12%
P/E Ratio	-0.22	3.17	22.12	362.98
Price / Sales	29.85	6,691.45	527.87	87,661.67
Price / Cash	62.50	13.13	41.34	27.85
Price / Book	0.07	86.77	9.94	7.79
Net Income	-£5.71M	-£96.07M	£3.57B	£5.89B
7 Day Performance	1.52%	-0.61%	-2.47%	0.17%
1 Year Performance	-59.84%	74.76%	26.55%	74.52%

ValiRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAL ValiRx	N/A	GBX 0.20 +5.3%	N/A	-59.8%	£1.49M	£49.78K	N/A	5,450	Positive News Gap Up High Trading Volume
NOG Nostrum Oil & Gas	1.3688 of 5 stars	GBX 3.50 +16.7%	GBX 4 +14.3%	-14.0%	£5.77M	£121.19M	N/A	30	Gap Up
SUN Surgical Innovations Group	N/A	GBX 0.50 +5.3%	N/A	-27.8%	£4.66M	£11.60M	N/A	80	Gap Down
WRES W Resources	N/A	N/A	N/A	N/A	£3.89M	£3.47M	N/A	66	Gap Down
CRC Circle Property	N/A	N/A	N/A	N/A	£1.02M	£7.57M	50.00	1,060	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:VAL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ValiRx (VAL) Competitors

VAL vs. NOG, SUN, WRES, CRC, and WEB

How does ValiRx compare to Nostrum Oil & Gas?

Summary

How does ValiRx compare to Surgical Innovations Group?

Summary

How does ValiRx compare to W Resources?

Summary

How does ValiRx compare to Circle Property?

Summary

How does ValiRx compare to Webis?

Summary

Media Sentiment Over Time

VAL vs. The Competition

ValiRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ValiRx (VAL) Competitors

VAL vs. NOG, SUN, WRES, CRC, and WEB

How does ValiRx compare to Nostrum Oil & Gas?

Which has stronger earnings & valuation, NOG or VAL?

Do analysts rate NOG or VAL?

Is NOG or VAL more profitable?

Do institutionals & insiders have more ownership in NOG or VAL?

Which has more volatility and risk, NOG or VAL?

Does the media favor NOG or VAL?

Summary

How does ValiRx compare to Surgical Innovations Group?

Is SUN or VAL more profitable?

Which has more risk and volatility, SUN or VAL?

Do insiders and institutionals have more ownership in SUN or VAL?

Which has stronger earnings & valuation, SUN or VAL?

Does the media favor SUN or VAL?

Summary

How does ValiRx compare to W Resources?

Which has higher earnings & valuation, VAL or WRES?

Is VAL or WRES more profitable?

Do institutionals and insiders hold more shares of VAL or WRES?

Does the media refer more to VAL or WRES?

Which has more risk & volatility, VAL or WRES?

Summary

How does ValiRx compare to Circle Property?

Which has higher earnings and valuation, VAL or CRC?

Is VAL or CRC more profitable?

Do institutionals and insiders hold more shares of VAL or CRC?

Does the media prefer VAL or CRC?

Which has more volatility and risk, VAL or CRC?

Summary

How does ValiRx compare to Webis?

Is WEB or VAL more profitable?

Which has higher valuation and earnings, WEB or VAL?

Do institutionals and insiders have more ownership in WEB or VAL?

Does the media prefer WEB or VAL?

Which has more volatility and risk, WEB or VAL?

Summary

Media Sentiment Over Time

VAL vs. The Competition

ValiRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools